Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.

Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Mod Rheumatol. 2014 May;24(3):405-9. doi: 10.3109/14397595.2013.844294. Epub 2013 Oct 21.

PMID:
24252016
2.

AA amyloidosis treated with tocilizumab: case series and updated literature review.

Courties A, Grateau G, Philippe P, Flipo RM, Astudillo L, Aubry-Rozier B, Fabreguet I, Fahd W, Fain O, Guggenbuhl P, Hachulla E, Papo T, Richez C, Sibilia J, Morel J, Berenbaum F, Sellam J; Club Rhumatismes Inflammation and the REGATE Registry.

Amyloid. 2015;22(2):84-92. doi: 10.3109/13506129.2014.1002031. Epub 2015 Jan 14. Review.

PMID:
25585627
3.

Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.

Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S46-53. Epub 2015 Jun 29. Review.

PMID:
26120866
5.

Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

Song SN, Yoshizaki K.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):307-16. doi: 10.1517/17425255.2015.992779. Epub 2014 Dec 10. Review.

PMID:
25491492
6.

Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases.

Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, Mokuda S, Murata Y, Takasugi K.

Mod Rheumatol. 2014 Jan;24(1):137-43. doi: 10.3109/14397595.2013.854048.

PMID:
24261770
7.

Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

McLaughlin M, Östör A.

Expert Opin Drug Saf. 2015 Mar;14(3):429-37. doi: 10.1517/14740338.2015.998198. Epub 2015 Jan 2. Review.

PMID:
25553607
8.

[Tocilizumab in rheumatoid arthritis].

Rueda Gotor J, Blanco Alonso R.

Reumatol Clin. 2011 Mar;6S3:S29-32. doi: 10.1016/j.reuma.2011.01.001. Epub 2011 Mar 23. Review. Spanish.

9.

Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.

Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.

J Rheumatol. 2013 Jul;40(7):1074-81. doi: 10.3899/jrheum.121389. Epub 2013 May 1.

PMID:
23637318
10.

Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.

Nakamura T.

Mod Rheumatol. 2008;18(2):109-18. doi: 10.1007/s10165-008-0035-2. Epub 2008 Mar 4. Review.

PMID:
18369528
11.

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.

Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators.

J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1.

PMID:
25834203
12.
13.

Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.

Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.

Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5.

PMID:
24252045
14.

Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.

Nakamura T, Kumon Y, Hirata S, Takaoka H.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):501-8. Epub 2014 Jun 23.

PMID:
24959698
15.

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.

McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, Codding CE, Carlson TH, Delles C, Lee JS, Sattar N.

Ann Rheum Dis. 2015 Apr;74(4):694-702. doi: 10.1136/annrheumdis-2013-204345. Epub 2013 Dec 24.

16.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.

PMID:
25231180
17.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
18.

Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.

Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S.

Clin Exp Rheumatol. 2007 Jul-Aug;25(4):518-22. Erratum in: Clin Exp Rheumatol. 2007 Sep-Oct;25(5):798.

PMID:
17888205
19.

Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.

Lazzerini PE, Acampa M, Capecchi PL, Fineschi I, Selvi E, Moscadelli V, Zimbone S, Gentile D, Galeazzi M, Laghi-Pasini F.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):332-9. doi: 10.1002/acr.22455.

20.

Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.

Ishiguro N, Atsumi T, Harigai M, Mimori T, Nishimoto N, Sumida T, Takeuchi T, Tanaka Y, Nakasone A, Takagi N, Yamanaka H.

Mod Rheumatol. 2017 Mar;27(2):217-226. doi: 10.1080/14397595.2016.1206507. Epub 2016 Jul 14.

PMID:
27414105

Supplemental Content

Support Center